M
Mark Zijlmans
Researcher at Erasmus University Rotterdam
Publications - 8
Citations - 366
Mark Zijlmans is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 6, co-authored 8 publications receiving 359 citations.
Papers
More filters
Journal ArticleDOI
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma
N W C J van de Donk,N Kröger,Ute Hegenbart,Paolo Corradini,J F San Miguel,H. Goldschmidt,José Antonio Pérez-Simón,Mark Zijlmans,Reinier Raymakers,Vittorio Montefusco,Francis Ayuk,M. H. J. Van Oers,Arnon Nagler,Leo F. Verdonck,H M Lokhorst +14 more
TL;DR: Donor lymphocyte infusion following non-myeloablative Allo-SCT is a valuable strategy for relapsed or persistent disease and there was a trend towards significance for time between transplantation and DLI, and response.
Journal ArticleDOI
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
Henk M. Lokhorst,Bronno van der Holt,Jan J. Cornelissen,Marie-Jose Kersten,Marinus H. J. van Oers,Reinier Raymakers,Monique C. Minnema,Sonja Zweegman,Jeroen Janssen,Mark Zijlmans,Gerard M. J. Bos,Nicolaas Schaap,Shulamiet Wittebol,Okke de Weerdt,Rianne Ammerlaan,Pieter Sonneveld +15 more
TL;DR: A donor versus no-donor analysis was performed of patients treated in the HOVON-50 study, a study that was originally designed to examine thalidomide combined with intensive therapy, to support a general application of allo-SCT in all myeloma patients as part of first-line therapy.
Journal ArticleDOI
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
Niels W.C.J. van de Donk,Nicolaus Kröger,Ute Hegenbart,Paolo Corradini,Jesús F. San Miguel,Hartmut Goldschmidt,José A. Pérez-Simón,Mark Zijlmans,Reinier Raymakers,Vittorio Montefusco,Francis Ayuk,Marinus H. J. van Oers,Arnon Nagler,Leo F. Verdonck,Henk M. Lokhorst +14 more
TL;DR: Donor lymphocyte infusions given in eight patients with multiple myeloma showed good results in establishing durable and stable engraftment with acceptable transplantation-related mortality (TRM) and excellent disease control in various hematologic malignancies.
Journal ArticleDOI
A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.
Jan J. Cornelissen,Bronno van der Holt,Eefke Petersen,Lars Vindeløv,Charlotte A. Russel,Martin Höglund,Johan Maertens,Harry C. Schouten,Eric Braakman,Monique M.C. Steijaert,Mark Zijlmans,Ineke Slaper-Cortenbach,Marc Boogaerts,Bob Löwenberg,Leo F. Verdonck +14 more
TL;DR: Outcome following T cell-depleted PBPCT critically depends on the number of CD3(+) T cells, whereby high T-cell numbers may blunt a favorable effect of higher CD34(+) cell numbers.
Journal ArticleDOI
Donor Versus No Donor Analysis of Newly Diagnosed Myeloma Patients Included in the HOVON 50/54 Study
Henk M. Lokhorst,Pieter Sonneveld,Bronno van der Holt,Marinus H. J. van Oers,Reinier Raymakers,Sonja Zweegman,Monique C. Minnema,Mark Zijlmans +7 more
TL;DR: This first preliminary analysis showed no improvement of tandem Auto Allo-RIC as part of first line therapy in myeloma as compared Auto-SCT followed by maintenance therapy.